Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | PRKACG | P22612 | 1/20 | 0.49 |
| ▸ | PRKACB | P22694 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | PRCP | P42785 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.35 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333525 | 1.00 | PRKACA (0.49) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| SCHEMBL1335278 | 1.00 | PRKACA (0.49) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| Hydrochloric Acid SCHEMBL1849039 | 0.98 | PRKACA (0.48) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| Trifluoroacetic Acid SCHEMBL14829349 | 0.86 | KDM1A (0.44) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| SCHEMBL14839568 | 0.85 | KCNH2 (0.43) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| SCHEMBL2602789 | 0.82 | SLC6A2 (0.44) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| SCHEMBL280628 | 0.81 | CSNK1D (0.43) | PRKACAPRKACGPRKACBPRCPCTSK | |
| Hydrochloric Acid SCHEMBL537239 | 0.81 | SLC6A2 (0.43) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| SCHEMBL22589151 | 0.81 | CHRNA7 (0.47) | PRKACAPRKACGPRKACBSLC6A2SLC6A3 | |
| SCHEMBL21717791 | 0.81 | MAPT (0.44) | PRKACAPRKACGPRKACBCTSKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1049431-C | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 2000-02-16 | — | — | CN | claimed |
| CN-1147254-A | Prodrugs of morpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 1997-04-09 | — | — | CN | claimed |
| EP-4747245-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| CN-122036605-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2026-05-15 | — | — | CN | disclosed |
| US-12612371-B2 | Sigma-1 receptor ligands and therapeutic uses thereof | UNIVERSITE DE STRASBOURG (FR) | 2026-04-28 | — | — | US | disclosed |
| WO-2025264672-A1 | INHIBITORS OF MOBILIZED COLISTIN RESISTANCE ENZYME (MCR-1) AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2025-12-26 | — | — | WO | disclosed |
| US-12497395-B2 | Small molecule bromodomain inhibitors and uses therof | CONVERGENE, LLC | 2025-12-16 | — | — | US | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| EP-0382185-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| CN-1087902-A | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 1994-06-15 | — | — | CN | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| CN-1046529-A | Carbostyril derivative | OTSUKA PHARMA CO LTD (JP) | 1990-10-31 | — | — | CN | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
| US-4680302-A | ANTIDEPRESSANTS | LABORATOIRE L. LAFON (FR) | 1987-07-14 | — | — | US | disclosed |
| US-3966801-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612371-B2 | Sigma-1 receptor ligands and therapeutic uses thereof | SIGMAR1, OPRL1, OPRM1 | PRKACA 3894/4885PRKACG 3917/4885PRKACB 4174/4885 |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | PRKACA 1749/4885PRKACG 1443/4885PRKACB 2008/4885 |
| US-12497395-B2 | Small molecule bromodomain inhibitors and uses therof | BRD4, BRPF3, BICRA | PRKACA 3819/4885PRKACG 3848/4885PRKACB 3302/4885 |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | PRKACA 1521/4885PRKACG 1544/4885PRKACB 1513/4885 |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | BMI1, EZH2, SUZ12 | PRKACA 1512/4885PRKACG 1376/4885PRKACB 1420/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | PRKACA 2597/4885PRKACG 2298/4885PRKACB 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.